In view of the current lack of any drug-like agent that can specifically target RPL24, our study also points toward RPL24 as a previously unrecognized subcellular target potentially contributing to the known anticancer activity of two approved cancer therapeutics, vorinostat and romidepsin, that are HDACi's like TSA, not to mention contributing to the anticancer mechanisms of investigational HDAC6-selective inhibitors like ACY-775. The gene discussed is HDAC6; the disease is cancer.